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Background: Engineered antibodies with pH responsive cell surface target antigen-binding affinities that decrease
at the acidic pH (5.5-5.8) within the endosomes have been found to have reduced susceptibility to degradation
within the lysosomes and increased serum half-life. Such pH responsive recombinant antibodies have been
developed for the treatment of cancer and cardiovascular disease. Engineered tenth type III human fibronectin
(Fn3) domains are emerging as a class of target antigen-binding biopharmaceuticals that could complement or be
superior to recombinant antibodies in a number of biomedical contexts. As such, there is strong motivation for
demonstrating the feasibility of engineering Fn3s with pH responsive antigen binding behavior that could lead to
improved Fn3 pharmacokinetics.
Results: A yeast surface-displayed Fn3 histidine (His) mutant library screening approach yielded epidermal growth
factor receptor (EGFR)-binding Fn3 domains with EGFR binding affinities that markedly decrease at endosomal pH;
the first reported case of engineering Fn3s with pH responsive antigen binding. Yeast surface-displayed His mutant
Fn3s, which contain either one or two His mutations, have equilibrium binding dissociation constants (KDs) that
increase up to four-fold relative to wild type when pH is decreased from 7.4 to 5.5. Assays in which Fn3-displaying
yeast were incubated with soluble EGFR after ligand-free incubation in respective neutral and acidic buffers showed
that His mutant Fn3 pH responsiveness is due to reversible changes in Fn3 conformation and/or EGFR binding
interface properties rather than irreversible unfolding.
Conclusions: We have established a generalizable method for efficiently constructing and screening Fn3 His
mutant libraries that could enable both our laboratory and others to develop pH responsive Fn3s for use in a wide
range of biomedical applications.
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Biopharmaceutical engineeringBackground
The tenth type III human fibronectin (Fn3) domain is a
useful and versatile scaffold for engineering high affinity
binders to a range of protein ligands associated with car-
diovascular disease [1] and numerous forms of cancer
[2]. The emerging impact of Fn3s in treating these and
other health conditions [3, 4] motivates the pursuit of
strategies for developing Fn3s with increased serum
half-life (t1/2). Engineering Immunoglobulin Gs (IgGs)
with pH responsive ligand binding affinity has been* Correspondence: proteinpete@gmail.com
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trafficking to and degradation within lysosomes after
IgG binding to cell surface target protein ligands and
subsequent endocytosis [5, 6]. Despite the positive effect
that pH responsiveness can have on IgG pharmacokinet-
ics there are no reports of engineering pH responsive
Fn3s for the purpose of increasing t1/2. Motivated by the
desirable outcomes with pH responsive IgGs, we have
established a general approach for engineering pH re-
sponsive Fn3s that could have extended t1/2s.
Ligand binding scaffolds with pH responsive ligand
binding affinity have been engineered using both site-
directed [7, 8] and random [7] mutagenesis. Site-directed
mutagenesis efforts have consisted of substituting wild
type residues, usually residing within regions of theess article distributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in any
ly credited. The Creative Commons Public Domain Dedication waiver (http://
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with the ligand, with histidine. The introduction of
His mutations is motivated by this amino acid’s side-
chain imidazole group having a pKa of approximately
6.0 [9]. In cases where the ionizable His sidechain ni-
trogen atom is involved in scaffold-ligand interactions,
decreasing the pH to below 6.0 can result in nitrogen
atom protonation that interferes with scaffold-ligand
interaction and reduces binding affinity. It is this po-
tential for pH-mediated reduction in binding affinity
that motivated the hypothesis that engineered ligand
binding scaffolds that contain site-directed His muta-
tions could have increased t1/2s [5, 9].
With respect to understanding how pH responsiveness
arising from His mutations can enhance binding scaffold
t1/2, one begins by noting that the pH at the cell surface
is near neutral (~7.4). Conversely, the pH within the
endosomes is acidic (~5.5-5.8). As such, endocytosis of
binding scaffold-cell surface receptor complexes results
in the complex undergoing a substantial shift in terms of
the pH of the surrounding environment. For cases in
which binding scaffold His mutations impart pH respon-
sive binding affinity, this pH shift promotes dissociation
of scaffold-receptor complexes within the endosome.
Whereas large fractions of intact scaffold-receptor com-
plexes are typically trafficked to the lysosome for degrad-
ation, both the scaffold and receptor components of the
complex are more likely to be recycled to the cell
surface, most probably in transport vesicles [9], if the
complex dissociates within the endosome (Fig. 1). It is
this increased cell surface recycling that is believed to
underlie the above noted observed increased in vivo







Fig. 1 Schematic of cell surface endocytosis and recycling for EGFR
and Fn3. Red arrows indicate trafficking of Fn3-EGFR complexes in
endosomes (orange circles) to lysosomes for degradation. Black
arrows denote movement of transport vesicles (yellow circles) carrying
dissociated Fn3 and EGFR molecules to the cell exterior. White
indentations denote sites of Fn3-EGFR complex internalization,
i.e., sites of endosome formationillustrating both the interplay among the phenomena
that govern Fn3 t1/2 and the mechanism by which pH
responsive ligand binding could increase t1/2 appears
in Additional file 1: Figure S1.
Yeast surface display is proven as a versatile platform
for engineering Fn3s with high affinity and specificity to-
ward a range of protein ligands [2]. Furthermore, both
site-directed and random mutagenesis have been suc-
cessfully employed in using yeast surface display to en-
gineer pH responsive binding scaffolds [7, 10]. These
precedents motivated our choosing yeast surface display
as our protein engineering platform for the development
of pH responsive Fn3s.
There are many examples of applying site-directed
amino acid substitution, insertion, or deletion within the
Fn3 domain’s three ligand-binding loops to achieve dra-
matic changes in Fn3 ligand binding specificity and/or
binding affinity [2, 11]. These examples motivate seeking
to achieve pH responsive ligand binding by targeting His
substitutions to these Fn3 loop regions. Fluorescence
activated cell sorting (FACS)-based screening of yeast
surface-displayed protein libraries has been used to iso-
late pH responsive Sso7d ligand binding scaffold pro-
teins from a random mutant library [7]. FACS has also
been used to enrich pH responsive light (VL) and heavy
(VH) chain antibody variable region domains from yeast-
displayed libraries in which His mutations were targeted
to the variable domain complementarity determining
regions (CDRs) [10]. Additionally, a camelid heavy chain
antibody domain (VHH) His mutant library in which His
mutations were targeted to CDR residues was screened
using phage display to yield pH responsive VHH clones
containing multiple His substitutions [8]. Combined
with the relative simplicity of library construction af-
forded by the continuous nature of codons representing
the residues within a given Fn3 loop, these outcomes
suggest that building and screening combinatorial Fn3
binding loop His mutant libraries is a viable strategy for
engineering Fn3s with pH responsive ligand binding
affinity.
In addition to loop residue substitutions, deletions,
and insertions, mutations to Fn3 framework residues
have been found to give rise to desired changes in Fn3
ligand binding affinity and specificity [2, 11]. The relatively
modest number of framework residues (~70) in a Fn3
domain make one-at-a-time construction and screening of
site-directed Fn3 single His mutants a tractable propos-
ition. Regardless of this feasibility, it is desirable to reduce
the labor and resources required to identify His substitu-
tions that impart pH responsiveness. Such a reduction
could be realized by constructing and screening site-
directed Fn3 single His mutants that are predicted to be
most likely to possess the desired pH responsive ligand
binding affinity. As such, we have employed a structure-
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tating a given framework residue to His will bring about
the desired pH responsive ligand binding affinity and have
used these probability estimates to identify a nonrandom,
information-guided order for Fn3 single His mutant con-
struction and screening.
The design of the structure-guided algorithm, which
quantifies the number of neighboring amino acids for
each Fn3 residue [12], that we have used to identify a
nonrandom order for Fn3 framework residue site-
directed Fn3 single His mutant construction and screen-
ing, has been motivated by two hypotheses. The first hy-
pothesis is that pH responsive ligand binding affinity
arising from Fn3 framework residue His mutations will
be the result of ionization-induced changes in the tertiary
structure of the Fn3 domain rather than the creation of
unfavorable Fn3-ligand interactions that are created by
His protonation. The second hypothesis is that mutating
amino acid sidechains that are buried within the Fn3
domain’s hydrophobic core will be much more likely to
disrupt Fn3 tertiary structure in a way that abolishes
ligand binding than to impart pH responsiveness. Taken
together, these hypotheses led us to develop a structure-
guided algorithm that, as discussed below, outputs the
number of neighboring residues for each amino acid rep-
resented in the Fn3 crystal structure.
In applying the number of neighbors outputs of this
algorithm to determine a nonrandom order for site-
directed single His mutant construction and screening,
we assume that substituting His for residues with the
greatest number of neighbors has a high probability of
leading to disruptions in Fn3 tertiary structure that abol-
ish ligand binding. We further posit that substituting
His for residues having the smallest number of neigh-
bors has a low probability of giving rise to pH responsive
ligand binding. This low probability is presumed by
virtue of these low number of neighbor residues partici-
pating in a relatively small number of interactions with
other amino acids within the Fn3 domain. This low
number of interactions is expected to reduce the likeli-
hood that protonation of a substituted His sidechain will
perturb Fn3 tertiary structure. The above assumptions
motivated our choosing to prioritize Fn3 framework
residues with an intermediate number of neighbors in
determining a nonrandom order for site-directed single
His mutant construction and screening.
Our choice of a parent Fn3 for pH responsiveness en-
gineering was motivated both by a desire to bind a cell
surface receptor that has clinical relevance and our wish-
ing to have a parent receptor-binding Fn3 with high re-
ceptor binding affinity at neutral pH. The latter criterion
arises from the observation that His mutations that give
rise to pH responsiveness tend to reduce ligand binding
affinity under both acidic and neutral conditions [8–10].High ligand binding affinity for the parent Fn3 helps
protect against the possibility that affinity reductions at
neutral pH will be large enough to reduce binding
affinity to cell surface ligands to a level that is not thera-
peutically relevant. An epidermal growth factor receptor
(EGFR)-binding Fn3, previously engineered by yeast
surface display, known as Clone A (CA), satisfied both
of the above criteria; EGFR has been targeted in treating
colon, neck, and breast cancer [13] and CA binds EGFR
with single-digit nanomolar affinity [11].
Results
Structure-guided quantification of Clone A (CA)
framework amino acid residue neighbors
The precedent [2, 11] for modifying Fn3 ligand binding
loops to modulate ligand binding specificity and affinity
made constructing site-directed loop residue single His
mutants and/or combinatorial loop residue His mutant
libraries a logical starting point for seeking to demonstrate
that His mutations can give rise to Fn3 variants with pH
responsive ligand binding affinity. Given however, that the
ability of framework mutations to influence Fn3 binding
affinity and specificity is understudied relative to the abil-
ity of loop mutations to modulate Fn3 ligand binding
properties, we were intrigued by the potential to assess
the degree to which framework His mutations might
enable pH responsive binding. As such, we chose to initi-
ate our pH responsiveness engineering pursuits by con-
structing and screening a collection of site-directed CA
framework residue single His mutants.
As discussed in the Background section, we developed
and applied a structure-guided algorithm, which is based
on an established method for quantifying amino acid
neighbors [12], to identify CA residues that possess an
intermediate number of neighbor residues. The algorithm,
which defines neighboring residues as having sidechain β
carbons that are within 10 Ǻ of each other, was applied to
the structure for the wild type tenth type III human fibro-
nectin domain (PDB entry 1FNA).
The respective ligand binding loop sequences for the
wild type and EGFR-binding CA Fn3 domains are highly
diverged. Conversely, the framework residue identities
for these two Fn3s differ at only one position (Additional
file 1: Figure S2). Given our emphasis on quantifying
neighbor amino acids for framework residues and the
generally surface exposed nature of loop residues, which
is expected to result in loop residues making a relatively
small contribution to framework residue neighbor amino
acid counts, we felt justified in using the wild type Fn3
crystal structure in quantifying neighbors for CA frame-
work residues.
The CA framework residue analysis found the average
number of framework residue neighbors to be 14.5 with
a standard deviation of 4.5 (Additional file 1: Table S1).
Fig. 2 Flow cytometry mean fluorescence units (MFU) versus
number of neighbors for 35 CA single His variants. MFU values
obtained for yeast incubated with 1 nM EGFR at pH 7.4
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and high numbers of neighbors as being below, within,
or above one standard deviation of the mean number of
neighbors. Using these criteria, the respective numbers
of framework residues with low, intermediate, and high
numbers of neighbors were 10, 41, and 16 (Additional
file 1: Table S1).
Calculated over all of the 91 Fn3 residues represented
in 1FNA the average number of neighbors was 14.0 with
a standard deviation of 4.4 (Additional file 1: Table S1).
Of the 24 loop residues, 7 have low numbers of neighbors
while 15 and 2 have respective intermediate and high
numbers of neighbors. This shift toward lower values in
the number of neighbors distribution for loop residues
relative to framework residues is in accord with the above
stated expectation that the generally surface exposed na-
ture of loop residues will result in their having fewer
neighbors than residues comprising the Fn3 framework.
The above noted high level of conservation of framework
residue primary sequence holds across the majority of
engineered Fn3 domains. As such, it is reasonable to
assume that the framework residue classifications deter-
mined here can be applied in determining an information-
guided, nonrandom order in which framework residue
site-directed single His mutants could be constructed and
screened for almost any Fn3 of interest.
Construction and screening of site-directed CA single His
mutants
We arbitrarily chose 20 CA residues from the intermedi-
ate number of neighbors group for site-directed mutagen-
esis to His. Additionally, in order to test the hypothesis
that mutating residues with large numbers of neighbors
would result in abolition of CA binding to EGFR we chose
15 CA residues from the high number of neighbors group
for site-directed His mutagenesis.
All 35 of the single His mutants were displayed on the
yeast surface at high levels as measured by flow cytome-
try. The observed inverse relationship between number
of neighbors and EGFR binding affinity at pH 7.4 as
measured by flow cytometry is illustrated by the scatter-
plot of Fig. 2. As shown by the flow cytometry MFU
(mean fluorescence unit) data in Additional file 1: Table S2,
the inverse relationship between number of neighbors
and EGFR binding affinity was relatively pH-independent
as respective MFU values at pH 7.4 and pH 5.5 var-
ied by 20 % or less for 28 of the 35 single His
mutants.
Eleven of the fifteen high neighbors group His mutants
had MFU values that were similar to those for the nega-
tive control at both pH 7.4 and pH 5.5 (Additional file 1:
Table S2). Three of the other four mutants in the high
neighbors group had notably reduced MFU values rela-
tive to wild type CA at both pHs. Only one of the 15 Hisvariants in this collection possessed binding affinity com-
parable to wild type CA. In contrast to the high number
of neighbors group, 12 of the 20 intermediate neighbors
group His mutants possessed MFU values that were at
least 50 % of the value measured for wild type CA at ei-
ther pH 7.4 or both pH 7.4 and pH 5.5.
Two of the single His mutants, F48H and T49H, pos-
sessed pH responsiveness screen MFU values that were
reduced by 75% or more at pH 5.5 relative to pH 7.4
(Fig. 3 & Additional file 1: Table S2). The appreciable
MFU reductions at pH 5.5 for these two mutants distin-
guished them from the other His mutants in the library;
the His mutants with the third and fourth greatest relative
reductions in MFU, Y36H and A57H, possessed relative
MFU decreases of approximately 40% (Additional file 1:
Table S2). The appreciable separation of the F48H and
T49H mutant relative MFU reduction values from those
for the other His mutant library members, along with the
MFU values for the F48H and T49H mutants being either
equivalent or not unduly reduced relative to wild type CA
at pH 7.4, motivated our focusing on the mutations at the
F48 and T49 positions in further Fn3 His mutant binding
affinity characterizations.
Given the precedent for multiple His mutations impart-
ing highly pH responsive binding affinity [5, 8, 10], we
constructed a F48H/T49H double His mutant to be ana-
lyzed along with the F48H and T49H single His mutants
in binding affinity titrations. We note here that an unin-
tended E47D mutation was present in both the F48H and
T49H single mutants due to an error in DNA oligo design
during the cloning process. This E47D mutation was
intentionally carried over into the F48H/T49H double His
mutant but was not incorporated into the parent CA
construct used in the flow cytometry affinity titrations
described below.
Fig. 3 Flow cytometry dot plots for yeast-displayed wild type, F48H, and T49H Fn3 CA. Cells incubated with 10 nM biotinylated EGFR. Y-axis denotes
phycoerythrin fluorescence corresponding to EGFR binding. X-axis denotes FITC fluorescence corresponding to myc tag yeast surface display
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affinity titrations
Our CA single His mutant screening dataset consisted of
single flow cytometric binding measurements at pH 7.4
and pH 5.5 for each mutant. As such, prior to initiating
soluble expression and purification of Fn3 domains for
use in surface plasmon resonance (SPR) binding affinity
measurement, we wished to further verify that the F48H,
T49H, and F48H/T49H CA mutants possessed pH re-
sponsive EGFR binding affinity. We also wanted to con-
firm that CA His mutant pH responsiveness was not
accompanied by unduly large decreases in EGFR binding
affinity at neutral pH. We achieved these objectives by
carrying out flow cytometric binding affinity titrations in
which the binding of yeast surface-displayed wild type CA
and the three His mutants to EGFR was measured across
a range of EGFR concentrations (Fig. 4).
The binding affinity titration results verified the in-
creased pH responsiveness of all three CA His mutants
relative to wild type CA (Table 1). T49H had the most
desirable EGFR binding property profile of the three
His mutants. This mutant possessed EGFR binding af-
finity (KD = 1.3 +/− 0.5 nM) that was similar to wild type
(KD = 1.7 +/− 0.1 nM) at pH 7.4 and a ratio of KDs
(pH 5.5:pH 7.4) that was increased more than four-fold,
i.e., from 1.4 +/− 0.2 to 6.3 +/− 0.7. The respective F48H
and F48H/T49H mutants, both of which possessed mildly
decreased EGFR binding affinity relative to wild type at
pH 7.4, had approximate two- and four-fold KD ratio in-
creases relative to wild type CA.
The EGFR binding histogram overlays of Fig. 5, which
present EGFR binding data collected at the EGFR con-
centrations that most strongly broke out differences inbinding affinity at respective neutral and acidic pH for
the CA His mutants, further demonstrate the appre-
ciable decreases in mutant binding affinity at pH 5.5
relative to pH 7.4 that are reflected by the KD data of
Table 1. The pH 5.5 His mutant histograms are notably
shifted toward lower fluorescence values relative to the
pH 7.4 His mutant histograms in all of these overlays.
Conversely, the pH 5.5 and pH 7.4 histograms for wild
type CA are nearly identical.
As shown by the surface display level measurement
flow cytometry histograms of Additional file 1: Figure S3,
the F48H mutation mildly decreased CA yeast surface dis-
play level while display for the F48H/T49H double mutant
was notably reduced. The surface display level for the
T49H mutant was similar to that for wild type CA.
Verifying reversibility of pH dependent decrease in binding
affinity for yeast-displayed wild Clone A His mutants
The need for clinically relevant pH responsive Fn3s to be
capable of undergoing multiple cycles of ligand binding,
endocytosis, and recycling to the cell exterior motivated
experiments to address the question of whether irre-
versible structural changes, such as partial or complete
unfolding of the protein, contributed to the observed
reductions in EGFR binding affinity for the yeast surface-
displayed CA His mutants at pH 5.5. We addressed this
question by incubating wild type and His mutant CA-
displaying yeast in either pH 7.4 or pH 5.5 buffer
(phosphate buffered saline with 1 mg/mL bovine serum
albumin, PBS-BSA) for one hour in the absence of ligand.
Subsequently, both the neutral and low pH buffer incuba-
tion cell samples were washed and incubated with various
concentrations of biotinylated EGFR in pH 7.4 PBS-BSA.
Fig. 4 Binding affinity titration curves for yeast-displayed wild type and His variant CA proteins. Y-axis denotes ratio of Mean Fluorescence Unit
(MFU) values measured via flow cytometry at a given EGFR concentration to MFUs measured at saturating EGFR concentration (50–100 nM) for
respective wild type and His variant CAs. X-axis denotes EGFR concentration. Measured:saturating MFU ratios for EGFR binding at pH 7.4 denoted
by blue markers; MFU ratios for EGFR binding at pH 5.5 denoted in red. Data points represent average values for two independent trials. Respective
blue and red lines connect data points for wild type CA binding to EGFR at pH 7.4 and pH 5.5. Error bars, which appear for T49H mutant data, denote
standard deviation for two independent trials
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tant CA binding affinity toward biotinylated EGFR was
independent of the pH at which the CA-displaying yeast
were incubated prior to ligand exposure. These results
show that the pH responsiveness of the yeast-displayed
CA His mutants is due to pH dependent, reversible
changes in protein conformation and/or ligand bind-
ing interface properties rather than the induction of
irreversible changes in protein structure under acidic
conditions.
Expression and purification of wild type and His mutant
CA in E. Coli
Having verified that the CA His mutants were more pH
responsive than wild type CA, not unduly compromised
with respect to binding affinity at pH 7.4, and not sus-
ceptible to irreversible structural changes under acidic
conditions, we proceeded with soluble expression andTable 1 EGFR binding affinity parameters for yeast-displayed wild ty
Fn3 Domain KD pH 5.5 (M)
Wild Type Clone A (2.4 +/− 0.4) •10−9
F48H (1.1 +/− 0.4) •10−8
T49H (8 +/− 2) •10−9
F48H/T49H (1.5 +/− 0.4) •10−8
Error bars denote standard deviations for two independent trials in which KDs were
conducted at pH 5.5 and pH 7.4 and carried out simultaneously. For each clone, tw
were calculated based on the data for each of the two independent pairs of EGFR bpurification of the wild type and all three His variant CA
proteins. As shown in the SDS-PAGE gel analysis of
Additional file 1: Figure S4, single step purification of E.
coli expression culture cell extracts using Co2+ affinity
resin enabled isolation of reasonably pure (~70-90%)
soluble CA wild type and His mutant proteins, all of
which contained C-terminal His6 tags. Our desire to em-
ploy the soluble Fn3s in SPR experiments, which provide
higher quality data when carried out with highly purified
proteins than when executed using lower purity protein
samples, motivated us to further enrich the soluble CA
wild type and His variant proteins via size exclusion
chromatography (SEC).
SEC analysis at pH 7.4 (Additional file 1: Figure S5) of
post-Co2+ affinity resin-purified wild type and His mu-
tant CA proteins showed that wild type CA existed as a
mixture of various molecular weight (MW) isoforms:
monomer (~12.5 kDa), dimer (~25 kDa), and high MWpe CA and His variants
KD pH 7.4 (M) KD Ratio (5.5/7.4)
(1.7 +/− 0.1) •10−9 1.4 +/− 0.2
(4.8 +/− 0.8) •10−9 2.3 +/− 0.4
(1.3 +/− 0.5) •10−9 6.3 +/− 0.7
(3 +/− 1) •10−9 5.2 +/− 0.4
determined by fitting data obtained in respective binding affinity titrations
o independent KD ratio values were obtained by dividing the KD values that
inding affinity titrations
Fig. 5 Binding histogram overlays showing pH responsiveness for respective F48H, T49H, and F48H/T49H CA mutants. X-axis denotes phycoerythrin
fluorescence corresponding to EGFR binding. Y-axis denotes number of yeast cells in sample analyzed with given level of EGFR binding. Wild type
(red-pH 7.4, pink-pH 5.5) incubated with 1.5 nM EGFR in all figure panels. F48H (dark green-pH 7.4, bright green-pH 5.5) incubated with 4 nM EGFR,
T49H (blue-pH 7.4, cyan-pH 5.5) incubated with 1.5 nM EGFR, and F48H/T49H (purple-pH 7.4, lavendar-pH 5.5) incubated with 12 nM EGFR. Unlabeled,
negative control yeast population histograms appear in orange in all figure panels. As shown in Additional file 1: Figure S3, F48H and F48H/T49H were
displayed at lower levels than T49H and wild type CA
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sively as high MW oligomers.
The high MW oligomers eluted in the SEC column
void volume fraction, a phenomenon generally observed
for proteins or protein complexes that possess column
gel matrix migration properties similar to those of pro-
tein species with MWs that are greater than the col-
umn’s upper MW limit (~660 kDa). Attempts to better
resolve this oligomer’s MW via native PAGE analysis
were unsuccessful; the high MW complexes did not mi-
grate through the polyacrylamide gel matrix in a way
that enabled MW estimation (data not shown). All three
of the wild type CA MW isoforms, as well as the
three His mutant CA oligomers, migrated at the same
MW (~12.5 kDa) upon reducing SDS-PAGE analysis
(Additional file 1: Figure S6). The yields of post-SEC
purified protein for the wild type and His mutant CA iso-
forms are presented in Additional file 1: Table S3.
Accurate comparison of SPR-measured wild type and
His mutant CA binding affinities or avidities requiresTable 2 Flow cytometry MFU values for CA-displaying yeast incubat
Fn3 Domain EGFR Concentration (nM)
Wild Type Clone A 1.5







Wild type and His variant CA-diplaying yeast were incubated with various concentr
ligand-free PBS-BSA with pH adjusted to either 5.5 or 7.4. EGFR concentrations were ch
affinity at pH 5.5 relative to pH 7.4 were most clearly broken out in KD titrations. Value
deviationsthat the proteins being characterized are in identical
oligomeric states. As such, prior to initiating SPR experi-
ments we sought to verify the stability of the wild type
and His mutant CA high MW oligomers at acidic pH.
As shown in Additional file 1: Figure S7, neither wild
type nor His mutant CAs appear as high MW oligomers
in the chromatograms when SEC is carried out at pH 5.5.
Wild type CA elutes as a mixture of dimeric and mono-
meric isoforms whereas there are no discernible elution
peaks for any of the CA His mutants.
We posit that multiple factors contributed to the con-
trast between wild type and His mutant CA proteins in
terms of the respective observed presence and absence of
defined elution peaks in the pH 5.5 SEC chromatograms.
The SDS-PAGE analysis of Additional file 1: Figure S4
shows that the E. coli culture expression levels for the CA
mutants were lower than for wild type CA. The SEC col-
umn was loaded with equal volumes of post-Co2+ affinity
resin-purified CA protein solution. As such, the mass of
CA His mutant protein injected onto the SEC columned with biotinylated EGFR after ligand-free buffer incubation
MFU - pH 5.5 Pre-incubation MFU - pH 7.4 Pre-incubation
1370 +/− 100 1340 +/− 100
1850 +/− 160 1650 +/− 100
650 +/− 20 620 +/− 80
1270 +/− 40 1200 +/− 100
1200 +/− 40 1250 +/− 120
1460 +/− 120 1600 +/− 30
150 +/− 10 160 +/− 20
220 +/− 30 240 +/− 20
ations of biotinylated EGFR in pH 7.4 PBS-BSA after one hour incubation in
osen to match or be similar to those at which reductions in CA EGFR binding
s represent averages for two independent trials. Error bars denote standard
Fig. 6 Binding histogram overlays showing that CA His mutants do not undergo irreversible conformational changes at low pH. X-axis denotes
phycoerythrin fluorescence corresponding to EGFR binding. Y-axis denotes number of yeast cells in sample analyzed with given level of EGFR
binding. Wild type (red-pH 7.4, pink-pH 5.5) incubated with 1.5 nM EGFR in all figure panels. F48H (dark green-pH 7.4, bright green-pH 5.5) incubated
with 4 nM EGFR, T49H incubated with 1.5 nM EGFR (blue-pH 7.4, cyan-pH 5.5), and F48H/T49H (purple-pH 7.4, lavendar-pH 5.5) incubated with 12 nM
EGFR. All incubations with EGFR performed in pH 7.4 buffer. The preceding pH values in parentheses and those appearing in the figure denote
ligand-free incubation buffer pH values. Unlabeled, negative control yeast population histograms appear in orange in all figure panels. As shown in
Additional file 1: Figure S3, F48H and F48H/T49H were displayed at lower levels than T49H and wild type CA
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ally, it is possible that the high MW CA His mutant oligo-
mers dissociate into a mixture of lower MW oligomers,
dimers, and monomers and that isoforms of a given MW
are heterogeneous with respect to protein structural con-
formation. The combination of such MW and conform-
ational heterogeneity and relatively low protein loading
would be expected to result in considerable diffusion of
the CA His mutants across the SEC column and prevent
the SEC chromatograms from featuring well-defined
elution peaks.
Regardless of what factors were responsible for the
absence of peaks in the pH 5.5 CA His mutant chro-
matograms it is clear that neither the wild type nor the
His mutant CA high MW oligomers are stable at acidic
pH. Given this observation we chose not to pursue the
planned SPR experiments. Although the inability to
quantify EGFR binding affinities for soluble wild type
and His mutant CA proteins is not a desirable outcome
the appreciable yields and high purity achieved for both
wild type and His variant CA bodes well for high level
production of Fn3s developed in the context of future
pH responsive Fn3 engineering pursuits.
Discussion
Our structure-guided algorithm for determining a non-
random order of Fn3 framework amino acid single His
mutant construction and screening enabled efficient
identification of Fn3 CA His mutants with pH respon-
sive binding affinity. The 15 high number of neighbors
mutants were constructed and screened for the purpose
of assessing the utility of our classification algorithm in
predicting Fn3 His mutant retention of ligand binding
affinity at neutral pH. As such, we can state that it has beenpossible to create multiple pH responsive CA variants by
way of constructing and screening just 20 site-directed
single His mutants.
This efficient isolation of pH responsive CA variants
groups our single His mutant construction and screening
strategy among random mutant [7] and site-directed His
mutant [7, 8, 10] library screening as proven approaches
for engineering pH responsive recombinant protein vari-
ants. Unlike both random and site-directed mutant library
screens, our screening strategy is not subject to inconclu-
sive outcomes in which one cannot determine whether an
inability to enrich pH responsive library members arises
from such clones not existing or their not being isolated
due to inadequate screening method fidelity and/or insuf-
ficient library sampling. As such, there are contexts, such
as making an initial demonstration of pH responsive bind-
ing for a given protein of interest, in which our single His
mutant screening approach is a more appropriate protein
engineering strategy than seeking to enrich pH responsive
clones from large libraries.
Also under the umbrella of desirable aspects of our
single His mutant screening approach, there are cases in
which one might want to engineer pH responsive vari-
ants of Fn3s that bind to different epitopes on the same
antigen [11]. In such situations, the time and materials
cost savings that can arise from constructing and
screening site-directed His mutants in a nonrandom
order, as opposed to constructing and screening a set
of single His mutants comprised of respective mem-
bers with substitutions at each of the ~ 100 amino acid
positions that constitute a given Fn3, become quite
considerable.
An additional opportunity for other researchers to bene-
fit from employing the methods that we have utilized in
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due conservation across different engineered Fn3s. This
high degree of conservation should make the outcomes of
our CA number of neighbors analysis useful for determin-
ing a nonrandom order of single His mutant construction
and screening for essentially any engineered tenth type III
human fibronectin of interest. As such, even researchers
who are not particularly well-versed in applying protein
structure-based calculations can benefit from our number
of neighbors algorithm by way of reducing the time and
materials costs associated with engineering pH responsive
Fn3s. Also in the vein of our CA His mutant engineering
results streamlining future pH responsive Fn3 engineering
efforts, the conservation of the F48 and T49 residues
across the majority of engineered Fn3 frameworks moti-
vates exploring the possibility that His mutations at these
positions could be common enablers of pH responsive lig-
and binding in the background of engineered Fn3s other
than CA.
Prior studies of soluble, purified CA binding to EGFR
do not report the presence of multiple MW isoforms
[11]. As such, we were surprised to find that both wild
type and His mutant CA existed in monomeric, dimeric,
and oligomeric states after Co2+ affinity resin purifi-
cation. Both our work and prior CA expression efforts
[11] utilized similar E. coli expression strains, expression
plasmids, and expression conditions. As such, it is likely
that wild type CA dimers and/or oligomers were present
in purified CA samples prepared by others but were
never detected as a result of single-step metal ion affinity
chromatography, with no subsequent SEC step, being
used for CA purification.
The instability and potential MW and conform-
ational heterogeneity of Fn3 oligomers prevents Fn3s
that oligomerize from being viable candidates for clin-
ical translation. As such, Fn3s that are being consid-
ered as parent scaffolds for yeast display engineering
should be expressed as soluble proteins, metal ion af-
finity chromatography purified, and analyzed by SEC
prior to initiating yeast surface display engineering
efforts. In this vein, we have been encouraged to learn that
others’ observations of multimerization of Fn3-like pro-
teins [13, 14] have spurred efforts to design recombinant
Fn3-like protein libraries comprised of members that
have high loop sequence diversity but low propensity
for multimerization.
In seeking insights regarding the structural basis of the
observed pH responsive binding for the F48H, T49H,
and F48H/T49H CA mutants we examined both the
1FNA crystal structure and a homology model of our
own construction in which the native Fn3 binding loops
were modified to match those of wild type CA. As can
sometimes be the case with such structural examinations,
we were not able to formulate any particularly stronghypotheses to explain the protein property of interest, in
this case pH responsive EGFR binding. We can however,
confidently state that the consecutive nature of the pH
sensitizing F48H and T49H mutations is coincidental; the
respective F48H and T49H sidechains are oriented at 180°
relative to each other and have nonoverlapping sets of
neighbor amino acids.
Based on our CA homology model, it appears that the
sidechain of the residue at position 47, which as noted
in the Results section is a Glu residue in wild type CA
but is mutated to Asp in all of the pH responsive mu-
tants, would interact with the sidechain of a His residue
that has been substituted for the native Thr at CA position
49 (Additional file 1: Figure S8). There is not however, any
apparent interaction between a substituted His residue at
position 48 and the sidechain, whether it be Asp or Glu,
of the residue appearing at position 47. Given this obser-
vation and the observed pH responsive binding of the
F48H CA mutant, it is unlikely that the E47D substitution
is a determinant of CA His mutant pH responsive ligand
binding.
The feasibility of engineering Fn3s that can bind to
almost any antigen of interest is well-established [2]. As
such, the generality of the approach that we have used
to create pH responsive CA His mutants raises the excit-
ing possibility of developing a collection of pH responsive
Fn3s that bind to a wide range of different respective cell
surface target antigens. Provided that an ample number of
the members of such a group of pH responsive Fn3s can
be expressed and purified in a stable monomeric form,
this set of engineered, pH responsive antigen binders
could enable a broad based assessment of the utility of
leveraging reduced Fn3 trafficking to the lysosomes and
the concomitant increase in cell surface recycling as a
strategy for improving Fn3 pharmacokinetics that could
be used as either a complement or an alternative to Fn3
PEGylation [15] for increasing t1/2.
Conclusions
Combining a structure-guided approach for deter-
mining a nonrandom order of Fn3 single His mutant
construction and screening with a yeast surface display-
based screening protocol has enabled efficient identi-
fication of His mutations that give rise to Fn3s with
pH responsive ligand binding. To our knowledge, the
pH responsive EGFR-binding Fn3 His mutants iso-
lated in this work are the first-ever engineered Fn3s
with pH responsive ligand binding affinity. We are
optimistic regarding the prospects for our setting this
Fn3 engineering precedent to enable both our laboratory
and others to develop pH responsive Fn3s that can have
an impact in the development of new and effective regi-
mens for treating cancer, cardiovascular disease, and other
health conditions.
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Structure-guided quantification of number of neighbors
for CA framework amino acids
The structure-guided algorithm we developed for quan-
tifying the number of neighbors for CA amino acids was
based on an established hydrogen bond potential func-
tion [12]. Our algorithm defines neighboring residues as
having sidechain β carbons that are within 10 Ǻ of each
other. For glycine, which does not have a sidechain β
carbon, the α carbon atom being within 10 Ǻ of another
amino acid’s β carbon was used to define neighboring
residues.
The distances between all pairs of representative atoms
were calculated to determine the number of neighbors
for each amino acid in the structure for the wild type
tenth type III human fibronectin domain (PDB entry
1FNA). Amino acids with neighbor counts within one
standard deviation of the average were classified as having
an intermediate number of neighbors. Respective amino
acids with neighbor counts one standard deviation above
and below the average were classified as having high and
low numbers of neighbors.
Construction of Clone A site-directed His mutants
Site-directed His mutations were introduced into the
CA Fn3 gene via overlap extension PCR using the wild
type CA yeast surface display plasmid as template in
conjunction with outer upstream primer ConSqLt (5′-
CTACTCTTTGTCAACGACTAC-3′) and outer down-
stream primer ConSqRt (5′-CATGGGAAAACATTTTT
TACG-3′). These respective oligonucleotides prime ap-
proximately 80 bases upstream and downstream of the
CA gene. Overlap PCR reactions were digested with
NheI and BamHI and ligated into similarly digested
pCTCON yeast surface display backbone vector. Ligation
products were transformed into chemically competent
DH5-alpha E. coli cells (New England Biolabs) and His
mutant sequences verified using the above primers.
Site-directed His mutant surface display plasmids that
sequenced correctly were transformed into S. cerevisiae
surface display strain EBY100 made competent using the
Zymo Research Frozen EZ-Yeast Transformation II kit.
Yeast surface-displayed Clone A His mutant flow cytometric
screening
Individual EBY100 colonies carrying CA surface display
plasmids were picked into 5 mL of SC-CAA media and
grown overnight at 30°C before being induced for 24 h
in 5 mL of SG-CAA at 30°C. Induced cultures were resus-
pended in phosphate buffered saline (PBS) with 1 mg/mL
bovine serum albumin (BSA) prior for flow cytometric
analysis of EGFR binding.
Recombinant human EGFR ectodomain produced in
Chinese hamster ovary cells, a gift from the laboratoryof Dr. Greg Adams at the Fox Chase Cancer Center, was
biotinylated using biotin-NHS (Pierce) and exchanged
into pH 7.4 PBS using a Zeba Spin desalting column
(Pierce). Flow cytometric screening for pH responsive-
ness was performed by incubating yeast cells with 1 nM
biotinylated EGFR ectodomain in PBS-BSA at both
pH 7.4 and pH 5.5 for 90 min at 25°C. These incuba-
tions included anti-myc IgY (Life Technologies) at a con-
centration of 20 μg/mL. Cells were washed and secondary
labeling was performed on ice by incubation with FITC-
conjugated goat anti-IgY (Jackson Immunoresearch) at
20 μg/mL and streptavidin-phycoerythrin (Jackson Immu-
noresearch) at 10 μg/mL in pH 7.4 PBS-BSA. FITC and
phycoerythrin fluorescence signals were measured using a
Becton Dickinson FACSort flow cytometer.
For yeast surface display wild type and His variant CA
affinity titrations CA-displaying yeast were incubated
with various concentrations of biotinylated EGFR for
90 min at 25°C. Cells were washed and secondary labeling
was performed on ice by incubation with streptavidin-
phycoerythrin in pH 7.4 PBS-BSA as above. Mean fluores-
cence values (MFUs) were determined for the entire
population, i.e., both displaying and nondisplaying yeast
cells. Equilibrium binding dissociation constant (KD)
values were determined using the Excel solver function
and a 3-parameter fit (KD, MFUrange and MFUmin) as de-
scribed [16].
In assays to verify that His variant CA mutant pH
responsiveness was not the result of irreversible changes
in protein conformation wild type or His variant CA-
displaying yeast were incubated in either pH 5.5 or
pH 7.4 PBS-BSA for 1 h at 25°C. Yeast cells were then
washed once in pH 7.4 PBS-BSA and incubated with
various concentrations (Table 2) of biotinylated EGFR in
pH 7.4 PBS-BSA for 90 min at 25°C. Cells were washed
and secondary labeling was performed on ice by incuba-
tion with streptavidin-phycoerythrin in pH 7.4 PBS-BSA.
MFU values for the entire yeast cell population were
measured via flow cytometry as described above.
Wild type & His mutant Clone A expression & purification
Wild type and His mutant CA genes were cloned into the
NcoI and BamHI sites of the pET28a expression vector
with C-terminal His6 tags and expressed in BL21(DE3)
E.coli cells using LB media containing 25 μg/mL of kana-
mycin. Five mL overnight cultures were used to inoculate
500 mL cultures. Five-hundred mL cultures were grown
at 37°C to A600 of 0.3 before induction with 0.5 mM IPTG.
CA proteins were expressed for 5 h at 37°C. Cells were
pelleted at 4,000 rpm (Beckman Coulter Avanti J-26S
centrifuge, JLA 8.1 fixed angle rotor) for 30 min and re-
suspended in lysis buffer (20 mM Tris–HCl, 150 mM
NaCl, pH 8.0) at a ratio of 10 mL of buffer to 1 g of wet
cell pellet. Cells were lysed by three passages through a
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Lysates were clarified by 30 min of centrifugation at
15,000 rpm (Beckman Coulter Avanti J-26S centrifuge, JA
25.50 fixed angle rotor).
CA protein in the lysate supernatants was purified by
affinity chromatography Talon Co2+ resin (Clontech).
Lysate was incubated with 1 mL of Talon resin pre-
equilibrated with lysis buffer at 25°C for 30 min with gen-
tle agitation. Resin was next packed into an empty 10 mL
column and washed with 30 mL of 20 mM Tris–HCl,
150 mM NaCl, 10 mM Imidazole, pH 8.0 before final
elution with 20 mM Tris–HCl, 150 mM NaCl, 500 mM
Imidazole, pH 8.0.
For the second protein purification step, i.e., size
exclusion chromatography, samples were run over a
Superdex 75 10/300 GL size exclusion column (GE
Healthcare) using an AKTA Pure FPLC system (GE
Healthcare). The column was calibrated using a Gel Filtra-
tion LMW Calibration Kit (GE Healthcare). Post-Talon
resin purified CA samples were injected in 500 μL vol-
umes and isocratic elution with PBS carried out at a flow
rate of 0.5 mL/min. Samples were sterile filtered using a
0.22 μM polyethersulfone syringe filter (Pall Life Sciences)
and CA concentrations determined via microscale
Bradford assay (BioRad). Low pH SEC was carried out as
above using 20 mM Na citrate, 150 mM NaCl, pH 5.5, as
the column running buffer.Additional file
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